Dopaminergic regulation of striatonigral tachykinin and dynorphin gene expression: A study with the dopamine uptake inhibitor GBR-12909

Molecular Brain Research

Volumn 35, Issue 1-2, 1996, Pages 197-210

  Sivam, S P ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE NORTHWEST   (United States)

Author keywords

6 hydroxydopamine; Cyclophilin; Dopamine; Dynorphin A(1 8); GBR 12909; Neurokinin A; Preprotachykinin; Prodynorphin; Substance P

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE UPTAKE INHIBITOR; DYNORPHIN; MESSENGER RNA; NEUROKININ A; OXIDOPAMINE; SPIPERONE; SUBSTANCE P; TACHYKININ; VANOXERINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; FEMALE; GENE EXPRESSION REGULATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT;

ANIMALIA;

EID: 0030053179     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0169-328X(95)00216-F     Document Type: Article

References (58)

1. Andersen, P.H., The dopamine uptake inhibitor GBR 12909: selectivity and molecular mechanism of action, Eur. J. Pharmacol., 166 (1989) 493-504.
2. Anderson, K.D. and Reiner, A., Extensive co-occurrence of substance P and dynorphin in striatal projection neurons: An evolutionarily conserved feature of basal ganglia organization, J. Comp. Neurol., 295 (1990) 339-369.
3. Bannon, M.J., Elliott, P.J. and Bunney, E.B., Striatal tachykinin biosynthesis: regulation of mRNA and peptide levels by dopamine agonist and antagonists, Mol. Brain Res., 3 (1987) 31-37.
4. Blum, M., Regulation of neuroendocrine peptide gene expression, Methods Enzymol., 168 (1989) 618-633.
5. Buck, S.H., Van Giersbergen, P.L.M. and Burcher, E., Tachykinins and their receptors: pharmacology, biochemistry and molecular biology, Neurochem. Int., 18 (1991) 167-170.
6. Chomczynski, P. and Sacchi, N., Single-step method of RNA isolation by acid guanidinium thiocynate-phenol-chloroform extraction, Anal. Biochem., 162 (1987) 156-159.
7. Civelli, O., Douglass, J., Goldstein, A. and Herbert, E., Sequence and expression of the rat prodynorphin gene, Proc. Natl. Acad. Sci. USA, 82 (1985) 4291-4295.
8. Danielson, P.E., Forss-Petter, S., Brow, M.A., Calavetta, L., Douglass, J., Milner, R.J. and Sutcliffe, J.G., p1B15: A cDNA clone of the rat mRNA encoding cyclophilin, DNA, 1 (1988) 261-267.
9. Dugaiczyk, A., Haron, J.A., Stone, E.M., Dennison, O.E., Rothblum, K.N. and Schwartz, R.J., Cloning and sequencing of a deoxyribonucleic acid copy of glyceraldehye-3-phosphate dehydrogenase messenger ribonucleic acid isolated from chicken muscle, Biochemisitry, 22 (1983) 1605-1613.
10. Gerfen, C.R., The neostriatal mosaic: Multiple levels of compartmental organization in the basal ganglia, Annu. Rev. Neurosci., 15 (1992) 285-320.
11. Gerfen, C.R., Engber, T.M., Mahan, L.C., Susel, Z., Chase, T.N., Monsma, F.J. and Sibley, D.R., D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons, Science, 250 (1990) 1429-1432.
12. Gerfen, C.R., McGinty, J.F. and Young, W.S. III, Dopamine differentially regulates dynorphin, substance P and enkephalin expression in striatal neurons: In situ hybridization histochemical analysis, J. Neurosci., 11 (1991) 1016-1031.
13. 3H]dopa in various regions of the brain, J. Neurochem., 13 (1966) 655-669.
14. Graybiel, A.M., Neuropeptides in the basal ganglia. In: J.B. Martin and J.D. Barchas (Eds.), Neuropeptides in Neurologic and Psychiatric Disease, Raven Press, New York, 1986, pp. 135-161.
15. Greenberg, M.E. and Ziff, E.B., Stimulation of 3T3 cells induces transcription of c-fos proto oncogene, Nature, 311 (1984) 433-438.
16. Habener, J.F., Regulation of polypeptide-hormone biosynthesis at the level of the genome, Am. J. Physiol., 249 (1985) 191-199.
17. Hanson, G.R., Letter, A.A., Merchant, K. and Gibb, J.W., Comparison of responses by striatonigral substance P and neurokinin A systems to methamphetamine treatment, Peptides, 7 (1986) 983-987.
18. Hanson, G.R., Merchant, K.M., Letter, A.A., Bush, L. and Gibb, J., Methamphetamine-induced changes in the striatal-nigral dynorphin system: role of D-1 and D-2 receptors, Eur. J. Pharmacol., 144 (1987) 245-246.
19. Haverstick, D.M. and Bannon, M.J., Evidence for dual mechanisms involved in methamphetamine-induced increases in striatal preprotachykinin mRNA, J. Biol. Chem., 264 (1989) 13140-13144.
20. Heikkila, R.E. and Manzino, L., Behavioral properties of GBR 12909, GBR 13069 and GBR 13098: specific inhibitors of dopamine uptake, Eur. J. Pharmacol., 103 (1984) 241-248.
21. Iadarola, M.J., Chuang, E.J., Yeung, C.L., Hoo, Y., Silverthorn, M. and Gu, J., Induction and suppression of proto-oncogenes in rat striatum after single or multiple treatments with cocaine or GBR-12909, NIDA Res. Monogr. Series, 125 (1993) 181-211.
22. Johnson, M., Bush, L.G., Gibb, J.W. and Hanson, G.R., Role of N-methyl-D-aspartate (NMDA) receptors in the response of extrapyramidal neurotensin and dynorphin A systems to cocaine and GBR 12909, Biochem. Pharmacol., 41 (1991) 649-652.
23. Kleven, M.S., Woolverton, W.L. and Seiden, L.S., Lack of long-term monoamine depletions following repeated or continuous exposure to cocaine, Brain Res. Bull., 21 (1988) 233-237.
24. Krause, J.E., Chirgwin, J.M., Carter, M.S., Xu, Z.S. and Hershey, A.D., Identification of three rat preprotachykinin mRNAs encode the neuropeptides substance P and neurokinin A, Proc. Natl. Acad. Sci. USA, 84 (1987) 881-885.
25. Krause, J.E., Cremins, J.D., Carter, M.S., Brown, E.R. and MacDonald, M.R., Solution hybridization-nuclease protection assays for sensitive detection of differentially spliced substance P-and neurokinin A-encoding messenger ribonucleic acids, Methods Enzymol., 168 (1989) 634-652.
26. Kubota, Y., Inagaki, S. and Kito, S., Innervation of substance P neurons by catecholaminergic terminals in the neostriatum, Brain Res., 375 (1986) 163-167.
27. Li, S.J., Sivam, S.P., McGinty, J.F., Huang, Y.S. and Hong, J.S., Dopaminergic regulation of tachykinin metabolism in the striatonigral pathway, J. Pharmacol. Exp. Ther., 243 (1987) 792-798.
28. Li, S.J., Sivam, S.P., McGinty, J.F., Jiang, H.K., Douglass, J., Calavetta, L. and Hong, J.S., Regulation of the metabolism of striatal dynorphin by the dopaminergic system, J. Pharmacol. Exp. Ther., 246 (1988) 403-408.
29. Lovtrup-Rein, H. and McEwen, B.S., Isolation and fractionation of rat brain nuclei, J. Cell Biol., 30 (1966) 405-415.
30. Marek, G.J., Vosmer, G. and Seiden, L.S., The effects of monoamine uptake inhibitors and methamphetamine on neostriatal 6-hydroxydopamine (6-OHDA) formation, short-term monoamine depletions and locomotor activity in the rat, Brain Res., 516 (1990) 1-7.
31. Melia, K.F. and Spealman, R.D., Pharmacological characterization of the discriminative-stimulus effects of GBR 12909, J. Pharmacol. Exp. Ther., 258 (1991) 626-632.
32. Morgan, J.I. and Curran, T., Stimulus-transcription coupling in neurons: role of cellular immediate-early genes, Trends Neurosci., 12(11) (1989) 459-462.
33. Nakanishi, S., Substance P precursor and kininogen: their structures, gene organizations and regulation, Physiol. Rev., 67 (1987) 1117-1142.
34. Nylander, I. and Terenius, L.H., Dopamine receptors mediate alterations in striatonigral dynorphin and substance P pathways, Neuropharmacology, 26 (1987) 1295-1302.
35. Palkovits, M., Isolated removal of hypothalamic of other brain nuclei of the rat, Brain Res., 59 (1973) 449-450.
36. Reid, M.S., Herrera-Marschitz, M., Hökfelt, T., Lindefors, N., Persson, H. and Ungerstedt, U., Striatonigral GABA, dynorphin, substance P and neurokinin A modulation of nigrostriatal dopamine release: Evidence for direct regulatory mechanisms, Exp. Brain Res., 82 (1990) 293-303.
37. Robertson, G.S., Vincent, S.R. and Fibiger, H.C., D1 and D2 dopamine receptors differentially regulate c-fos expression in striatonigral and striatopallidal neurons, Neuroscience, 49 (1992) 285-296.
38. Robertson, H.A., Paul, M.L., Moratalla, R. and Graybiel, A.M., Expression of the immediate early gene c-fos in basal ganglia: Induction by dopaminergic drugs, Can. J. Neurol. Sci., 18 Suppl. (1991) 380-383.
39. Sambrook, J., Fritsch, E.F. and Maniatis, T., Molecular Cloning: A Laboratory Manual, Cold Spring Habor Laboratory Press, Cold Spring Harbor, NY, 1989, pp. 1.21-1.52.
40. Seeman, P. and Van Tol, H.H.M., Dopamine receptor pharmacology, Trends Pharmacol. Sci., 15 (1994) 264-270.
41. Sheng, M. and Greenberg, M.E., The regulation and function of c-fos and other immediate early genes in the nervous system, Neuron, 4 (1990) 477-485.
42. Sivam, S.P., Cocaine selectively increases striatonigral dynorphin levels by a dopaminergic mechanism, J. Pharmacol. Exp. Ther., 250 (1989) 818-824.
43. 1 dopamine receptor-mediated substance P depletion in the striatonigral neurons of rats subjected to neonatal dopaminergic denervation: Implications for self-injurious behavior, Brain Res., 500 (1989) 119-130.
44. Sivam, S.P., Influence of monoamine oxidase inhibitors on striatonigral dynorphin system: a study with deprenyl and clorgyline, Neuropeptides, 25 (1993) 35-45.
45. Sivam, S.P., GBR-12909-induced self-injurious behavior and alterations in dynorphin and substance P systems in rat striatum, Soc. Neurosci. Abstr., 20 (1994) 228. (Abstract).
46. Sivam, S.P., Dopaminergic modulation of serotonin metabolism in rat striatum: a study with dopamine uptake inhibitor GBR-12909, Life Sci., 56 (1995) PL467-472.
47. Sivam, S.P., Breese, G.R., Krause, J.E., Napier, T.C., Mueller, R.A. and Hong, J.-S., Neonatal and adult 6-hydroxydopamine-induced lesions differentially alter tachykinin and enkephalin gene expression, J. Neurochem., 49 (1987) 1623-1633.
48. Sivam, S.P. and Krause, J.E., Compensatory activation of substance P biosynthesis by L-dihydroxyphenylalanine in striatonigral neurons of neonatal dopaminergic denervated rats, J. Pharmacol. Exp. Ther., 254 (1990) 433-439.
49. Sivam, S.P. and Krause, J.E., The adaptation of enkephalin, tachykinin and monoamine neurons of the basal ganglia following neonatal dopaminergic denervation is dependent on the extent of dopamine depletion, Brain Res., 536 (1990) 169-175.
50. Sivam, S.P., Takeuchi, K., Li, S., Douglass, J., Civelli, O., Calvetta, L., Herbert, E., McGinty, J.F. and Hong, J.S., Lithium increases dynorphin A(1-8) and prodynorphin mRNA levels in the basal ganglia of rats, Mol. Brain Res., 3 (1988) 155-164.
51. Smith, R.D., Cooper, B.R. and Breese, G.R., Growth and behavioral changes in developing rats treated intracisternally with 6-hydroxydopamine: evidence for involvement of brain dopamine, J. Pharmacol. Exp. Ther., 185 (1973) 609-619.
52. Sonsalla, P.K., Gibb, J.W. and Hanson, G.R., Nigrostriatal dopamine actions on the D2 receptors mediate methamphetamine effects on the striatonigral substance P system, Neuropharmacology, 25 (1986) 1221-1230.
53. Thompson, L.A., Matsumoto, R.R., Hohmann, A.G. and Walker, J.M., Striatonigral prodynorphin: A model system for understanding opioid peptide function, Ann. NY Acad. Sci., 579 (1990) 192-203.
54. van der Zee, P., Koger, H.S., Gootjes, J. and Hespe, W., Aryl 1,4-dialk(en)ylpiperazines as selective and very potent inhibitors of dopamine uptake, Eur. J. Med. Chem., 15 (1980) 363-370.
55. Weber, E., Evans, C.J. and Barchas, J.D., Predominance of the aminoterminal octapeptide fragment of dynorphin immunoreactive striatonigral pathway, Nature, 299 (1982) 77-79.
56. White, J.D. and LaGamma, E.F., Neuropeptide gene transcription in central and peripheral nervous system tissues by nuclear run-on assay, Methods Enzymol., 168 (1989) 681-690.
57. Winer, B.J., Statistical Principles in Experimental Design, McGraw-Hill, New York, 1983.
58. Young, III, W.C., Bonner, T.I. and Brann, M.R., Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain, Proc. Natl. Acad. Sci. USA, 83 (1986) 9827-9831.